Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases.
Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases.
复制标题
DOI：
10.1093/rap/rkac008
复制
发表时间：
2022
影响因子：
3.1
通讯作者：
Abasolo L
中科院分区：
文献类型：
--
作者：
Leon L;Perez-Sancristobal I;Madrid A;Lopez-Pedraza L;Colomer JI;Lerma S;Lois P;Mucientes A;Rodriguez-Rodriguez L;Fernandez-Gutierrez B;Abasolo L
我们旨在描述2019冠状病毒病（COVID-19）导致的风湿病和肌肉骨骼疾病（RMD）患者入院后的持续症状和后遗症，评估自身免疫性风湿病（ARDs）与非自身免疫性风湿病和肌肉骨骼疾病（NARDs）对持续症状和后遗症的作用。我们进行了一项观察性研究，纳入了在马德里一家风湿病诊所就诊的RMD患者，这些患者因COVID-19（2020年3月至5月）而需要住院，并存活了下来。这项研究从出院时开始，一直持续到2020年10月。主要结局是与COVID-19相关的症状和后遗症的持续。自变量为RMD组（ARD和NARD）。协变量包括社会人口统计学、临床和治疗数据。我们采用多变量logistic回归模型评估RMD组主要结局的风险。我们纳入105例患者，其中51.5%患有ARD， 68.57%报告至少一种持续症状。最常见的症状是呼吸困难、疲劳和胸痛。31例患者有后遗症。其中包括10.4%的患者肺损伤，10%的患者淋巴细胞减少，视网膜中央静脉阻塞和视神经炎。两名患者死亡。11例患者因COVID-19问题再次入院（16.7% ARD vs 3.9% NARD; P = 0.053）。在最终模型中，RMD组间无统计学差异。与其他人群一样，许多RMD患者有持续的症状。肺损伤是最常见的后遗症。与NARD相比，ARD在持续症状或后果方面似乎没有区别，尽管由于COVID-19， ARD可能有更多的再入院率。
We aimed to describe persistent symptoms and sequelae in patients with rheumatic and musculoskeletal diseases (RMD) after admission owing to coronavirus disease 2019 (COVID-19), assessing the role of autoimmune rheumatic diseases (ARDs) compared with non-autoimmune rheumatic and musculoskeletal diseases (NARDs) on persistent symptoms and sequelae. We performed an observational study including RMD patients who attended a rheumatology clinic in Madrid and required admission owing to COVID-19 (between March and May 2020) and survived. The study began at discharge and ran until October 2020. Main outcomes were persistence of symptoms and sequelae related to COVID-19. The independent variable was the RMD group (ARD and NARD). Covariates included sociodemographics, clinical and treatment data. We ran a multivariate logistic regression model to assess the risk of the main outcomes by RMD group. We included 105 patients, of whom 51.5% had ARD and 68.57% reported at least one persistent symptom. The most frequent symptoms were dyspnoea, fatigue and chest pain. Sequelae were recorded in 31 patients. These included lung damage in 10.4% of patients, lymphopenia in 10%, a central retinal vein occlusion and an optic neuritis. Two patients died. Eleven patients required re-admission owing to COVID-19 problems (16.7% ARD vs 3.9% NARD; P = 0.053). No statistically significant differences were found between RMD groups in the final models. Many RMD patients have persistent symptoms, as in other populations. Lung damage is the most frequent sequela. Compared with NARD, ARD does not seem to differ in terms of persistent symptoms or consequences, although ARD might have more re-admissions owing to COVID-19.
登录
查看更多内容
影响因子：
13.8
作者：
Bellan M;Soddu D;Balbo PE;Baricich A;Zeppegno P;Avanzi GC;Baldon G;Bartolomei G;Battaglia M;Battistini S;Binda V;Borg M;Cantaluppi V;Castello LM;Clivati E;Cisari C;Costanzo M;Croce A;Cuneo D;De Benedittis C;De Vecchi S;Feggi A;Gai M;Gambaro E;Gattoni E;Gramaglia C;Grisafi L;Guerriero C;Hayden E;Jona A;Invernizzi M;Lorenzini L;Loreti L;Martelli M;Marzullo P;Matino E;Panero A;Parachini E;Patrucco F;Patti G;Pirovano A;Prosperini P;Quaglino R;Rigamonti C;Sainaghi PP;Vecchi C;Zecca E;Pirisi M
通讯作者：
Pirisi M
影响因子：
20.3
作者：
Roberts, Lara N.;Whyte, Martin B.;Arya, Roopen
通讯作者：
Arya, Roopen
DOI：
10.1136/bmj.i6583
发表时间：
2017-02-15
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Martineau AR;Jolliffe DA;Hooper RL;Greenberg L;Aloia JF;Bergman P;Dubnov-Raz G;Esposito S;Ganmaa D;Ginde AA;Goodall EC;Grant CC;Griffiths CJ;Janssens W;Laaksi I;Manaseki-Holland S;Mauger D;Murdoch DR;Neale R;Rees JR;Simpson S Jr;Stelmach I;Kumar GT;Urashima M;Camargo CA Jr
通讯作者：
Camargo CA Jr
影响因子：
4.5
作者：
Sung, Ho Kyung;Kim, Jin Yong;Oh, Myoung-don
通讯作者：
Oh, Myoung-don
影响因子：
2.6
作者：
Gorzkowski, Victor;Bevilacqua, Sibylle;Duc Trung Nguyen
通讯作者：
Duc Trung Nguyen